Interview With Christopher D’Angelo, MD: Current Frontline Treatment of DLBCL Beyond R-CHOP

Interview With Gilles Salles, MD, PhD: Novel Treatments in DLBCL

Interview With Shani Irby, ANP-BC: CAR T-Cell Therapy in DLBCL

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We encourage you to take a look around at all the cutting-edge information, education, research, and other resources we’ve curated to empower your practice in this disease space. If you have any feedback or questions, please contact jadpro-editor@broadcastmed.com

Katherine L. Byar, MSN, APN, BC, BMTCN

Oncology/ Hematology Nurse Practitioner

Fred & Pamela Buffett Cancer Center

Nebraska Medicine
Omaha, Nebraska

International Prognostic Index (IPI) Calculator

NCCN Guidelines on Diffuse Large B-Cell Lymphoma

DLBCL Trials on Clinicaltrials.gov

Lymphoma Research Foundation

Leukemia & Lymphoma Society

The Lancet Haematology

Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study

Clinical and Molecular Hepatology

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

DLBCL Resource Center

Interview With Christopher D’Angelo, MD: Current Frontline Treatment of DLBCL Beyond R-CHOP

International Prognostic Index (IPI) Calculator

NCCN Guidelines on Diffuse Large B-Cell Lymphoma

DLBCL Trials on Clinicaltrials.gov

Lymphoma Research Foundation

Leukemia & Lymphoma Society

The Lancet Haematology

Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study

Clinical and Molecular Hepatology

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Oncology Nursing News

Epcoritamab obtains accelerated approval for relapsed/refractory DLBCL

Cancers

Factors affecting health-related quality of life among survivors of non-Hodgkin lymphoma: A population-based study

Journal of Clinical Oncology

Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International metabolic prognostic index

Blood Cancer Journal

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Scientific Reports

Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

U.S. Food and Drug Administration

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma

Cure

Targeted therapies shake up the DLBCL treatment paradigm, expert says

Transplantation and Cellular Therapy

Assessment of salvage regimens post CAR-T cell therapy for patients with diffuse large B-cell lymphoma

Follicular Lymphoma Transformed to DLBCL

Fast Facts #12: Long-Term Survivorship